| abstract |
A pharmaceutical composition containing specific nicotine-related alkaloids in a nasal formulation, or in combination with other compounds from tobacco and/or natural plant species, in nasal, oral or ocular formulations, for use as an effective treatment for viral infections including Covid-19. Novel compositions comprise one or more of the compounds nicotine, nornicotine, anabasine, anabaseine, anatabine, cotinine, myosmine, N-formyl-nicotine, isonicotine, and nicotyrine; and one or more of the compounds S-allylcysteine, S-allyl mercaptocysteine, 6-shogaol, 6 gingerol, curcumin and piperine; wherein the composition is in the form of a liquid or powdered nasal, liquid oral, or liquid ocular formulation, except that neither curcumin or piperine are not present in a nasal or ocular formulation. |